Vertex beefs up gene-editing work with new discovery pact; Verrica shares jump on molluscum drug data; J&J's inks two deals
→ Four months after Vertex $VRTX and its allies at CRISPR Therapeutics got started on their first trial using gene editing tech for beta thalassemia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
